期刊文献+

利格列汀在血糖控制不良的2型糖尿病中的疗效及对胰岛功能的影响 被引量:12

下载PDF
导出
摘要 目的观察利格列汀在血糖控制不良的2型糖尿病患者中的疗效及对胰岛功能的影响。方法选择40例血糖控制不良的2型糖尿病患者,随机分成两组,观察组20例,在原有治疗方案的基础上加用利格列汀(5 mg/次,1次/d);对照组20例,继续原有治疗方案加安慰剂,持续24周后检测相关指标。结果观察组治疗后空腹血糖(FPG)、餐后2 h血糖(2h PBG)、糖化血红蛋白(Hb A_(1C))、体质指数(BMI)、胰岛素抵抗指数(HOMA-IR)均显著下降(P<0.05),而胰岛β细胞功能指数HOMA-β有一定升高。结论利格列汀能有效降低FPG、2h PBG、Hb A_(1C)、BMI,并改善胰岛β细胞功能。
出处 《广东医学》 CAS 2018年第S1期223-224,226,共3页 Guangdong Medical Journal
  • 相关文献

参考文献2

二级参考文献46

  • 1World health organization. Diabetes[EB/OL]. (2011-08)[2012- 01]. http ://www.who.int/mediacentre/factsheets/fs312/en/index.html.
  • 2ECKHARDT M, LANGKOPF E, MARK M, et ol. 8-(3-(R)- Aminopiperidin- 1 - yl) - 7 - but- 2- ynyl- 3- methyl- 1 - (4- methyl- quinazolin - 2 - ylmethyl) - 3, 7 - dihydropurine - 2, 6 - dione (BI 1356), a highly potent, selective, long- acting, and orally bioavailable DPP-4 inhibitor for the treatment of type 2 diabetes [J]. J Med Chem, 2007, 50(26): 6450-6453.
  • 3NAUCK MA. Incretin- based therapies for type 2 diabetes mellitus : properties, functions, and clinical implications[J]. Am J Med, 2011, 124(1 Suppl): S3-S18.
  • 4THOMAS L, ECKHARDT M, LANGKOPF E, et al. (R)-8- (3 - Amino - piperidin - 1 - yl) - 7 - but - 2 - ynyl - 3 - methyl - 1 - (4 - methyl - quinazolin - 2 - ylmethyl) - 3, 7 - dihydro - purine - 2, 6 -dione (BI 1356), a novel xanthine-based dipeptidyl peptidase 4 inhibitor, has a superior potency and longer duration of action compared with other dipeptidyl peptidase- 4 inhibitors[J]. J Pharmacol Exp Ther, 2008, 325(1): 175-182.
  • 5FORST T, UHLIG-LASKE B, RING A, et ol. The oral DPP-4 inhibitor linagliptin significantly lowers HbA~c after g weeks of treatment in patients with type 2 diabetes mellitus[J]. Diabetes Obes Metab, 2011, 13(6): 542-550.
  • 6HEISE T, GRAEFE- MODY EU, HUTYNER S, et al. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase- 4 inhibitor in male type 2 diabetes patients[J]. Diabetes Obes Metab, 2009, 11 (8): 786-794.
  • 7TIWARI A. Linagliptin, a dipeptidyl peptidase- 4 inhibitor for the treatment of type 2 diabetes[J]. Curr Opin Investig Drugs, 2009, 10(10): 1091-1104.
  • 8FUCHS H, TILLEMENT JP, URIEN S, et ol. Concentration- dependent plasma protein binding of the novel dipeptidyl peptidase 4 inhibitor BI 1356 due to saturable binding to its target in plasma of mice, rats and humans[J]. J Pharm Pharmacol, 2009, 61(1): 55-62.
  • 9RETLICH S, DUVAL V, RING A, et ol. Pharmacokinetics and pharmacodynamics of single rising intravenous doses (0.5 nag - 10 rag) and determination of absolute bioavailability of the dipeptidyl peptidase-4 inhibitor linagliptin (BI 1356) in healthy male subjects[J]. Clin Pharmacokinet, 2010, 49(12): 829-840.
  • 10SCHEEN AJ. Pharmacokinetics of dipeptidylpeptidase- 4 inhibitors[J]. Diabetes Obes Metab, 2010, 12(8): 648-658.

共引文献29

同被引文献136

引证文献12

二级引证文献106

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部